Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

767
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
767
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

1.2K
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
1.2K
Mitral Stenosis II: Clinical features and Diagnostic Tests01:23

Mitral Stenosis II: Clinical features and Diagnostic Tests

463
Mitral stenosis is a heart condition in which the mitral valve, which allows blood to flow from the left atrium to the left ventricle, becomes narrowed or stenotic. This narrowing hinders blood flow and leads to clinical symptoms requiring specific medical evaluations and management strategies. The following overview outlines the clinical symptoms, assessments, diagnostic findings, prevention methods, and treatments for mitral stenosis.Clinical ManifestationsDyspnea (shortness of breath): This...
463
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

3.2K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
3.2K
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

456
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
456
Aneurysm II: Clinical Manifestations and Diagnostic Studies01:21

Aneurysm II: Clinical Manifestations and Diagnostic Studies

537
Thoracic, aortic arch and abdominal aneurysms are significant vascular conditions that can present with various clinical manifestations and lead to serious complications. Understanding these manifestations and the appropriate diagnostic studies is essential for effective management and treatment.Thoracic Aortic AneurysmsThoracic aortic aneurysms often remain asymptomatic until they reach a size that impinges on adjacent structures. They typically cause deep, diffuse chest pain that radiates to...
537

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Operative management of pediatric radiation-induced cavernous malformations: insights from a single-center cohort.

Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery·2026
Same author

Molecular dynamics simulation of high slip flow of water confined between graphene nanochannels at experimentally accessible shear rates.

The Journal of chemical physics·2026
Same author

Management Strategies and Long-Term Outcomes of Pediatric Brainstem Cavernous Malformations: Conservative Management vs Surgery.

Neurosurgery·2026
Same author

Study of Arbitrarily Low Shear Rate Rheology Using Dissipative Particle Dynamics.

Journal of chemical theory and computation·2026
Same author

Management of pediatric patients with moyamoya arteriopathy and middle aortic syndrome: a retrospective single-institution case series.

Journal of neurosurgery. Pediatrics·2026
Same author

Understanding stroke risk phenotypes in pediatric patients with sickle cell disease and concurrent moyamoya arteriopathy: insights from 61 cases at a single institution.

Journal of neurosurgery. Pediatrics·2026

Related Experiment Video

Updated: Apr 7, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

6.0K

Moyamoya Biomarkers.

Edward R Smith1

  • 1Department of Neurological Surgery, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA.

Journal of Korean Neurosurgical Society
|July 17, 2015
PubMed
Summary
This summary is machine-generated.

Moyamoya disease (MMD) biomarkers, including proteins, cells, and genes, are being developed to improve diagnosis and predict the course of this rare brain condition. Research focuses on identifying reliable markers for better patient outcomes.

Keywords:
BiomarkerGeneticsMoyamoyaProteomeStroke

More Related Videos

Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions
07:30

Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions

Published on: April 23, 2021

3.5K
Quantification of Neurovascular Protection Following Repetitive Hypoxic Preconditioning and Transient Middle Cerebral Artery Occlusion in Mice
09:48

Quantification of Neurovascular Protection Following Repetitive Hypoxic Preconditioning and Transient Middle Cerebral Artery Occlusion in Mice

Published on: May 4, 2015

14.4K

Related Experiment Videos

Last Updated: Apr 7, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

6.0K
Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions
07:30

Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions

Published on: April 23, 2021

3.5K
Quantification of Neurovascular Protection Following Repetitive Hypoxic Preconditioning and Transient Middle Cerebral Artery Occlusion in Mice
09:48

Quantification of Neurovascular Protection Following Repetitive Hypoxic Preconditioning and Transient Middle Cerebral Artery Occlusion in Mice

Published on: May 4, 2015

14.4K

Area of Science:

  • Neurology
  • Vascular Biology
  • Biomarker Discovery

Background:

  • Moyamoya disease (MMD) is a progressive arteriopathy affecting intracranial arteries, characterized by heterogeneous clinical presentations.
  • Variability in MMD progression and treatment response necessitates improved diagnostic and prognostic tools.
  • Recent advancements in biomarker research offer potential for better understanding and management of MMD.

Purpose of the Study:

  • To review current categories of biomarkers relevant to Moyamoya disease.
  • To discuss the potential applications and limitations of these biomarkers.
  • To highlight the significance of biomarker development in MMD diagnosis and prognosis.

Main Methods:

  • Literature review of existing research on Moyamoya disease biomarkers.
  • Categorization of biomarkers into proteins, cells, and genes.
  • Analysis of the diagnostic and prognostic potential of identified biomarkers.

Main Results:

  • Proteins, cells, and genes represent key categories of MMD biomarkers.
  • Imaging patterns can also serve as diagnostic biomarkers.
  • Biomarkers show promise in identifying disease presence and predicting its clinical course.

Conclusions:

  • Biomarker development is crucial for improving the diagnosis and prognosis of Moyamoya disease.
  • Further research is needed to overcome limitations and fully realize the clinical applications of MMD biomarkers.
  • Identifying reliable biomarkers will aid in personalized treatment strategies for MMD patients.